Yale-Led Clinical Trial Investigates Anti-Inflammatory Drug Adalimumab to Prevent Parkinson’s Disease in High-Risk Patients

In a groundbreaking approach to neurodegenerative disease research, a team of Yale-led scientists has launched a major clinical trial to investigate whether the anti-inflammatory drug adalimumab can delay or completely prevent the onset of Parkinson’s disease. The study targets individuals diagnosed with rapid eye movement sleep behavior disorder (RBD), a distinct sleep condition that carries a remarkably high risk of progressing into Parkinson’s disease or related neurological disorders over time.

The clinical trial is spearheaded by prominent researchers at the Yale School of Medicine, including Dr. Jesse Cedarbaum, professor of neurology, and Dr. David Hafler, the William S. and Lois Stiles Edgerly Professor of Neurology. This ambitious research initiative represents the first clinical trial of its kind designed to test whether a targeted pharmaceutical intervention can halt or significantly slow the trajectory of Parkinson’s disease before any clinical motor symptoms manifest in vulnerable populations.

For decades, medical science has recognized that the classic motor hallmarks of Parkinson’s disease—such as resting tremors, muscle rigidity, and slowed movement—are preceded by warning signs that can emerge long before a formal diagnosis is made. Among the most reliable and alarming precursors is rapid eye movement sleep behavior disorder, a parasomnia characterized by the physical enactment of dreams, sometimes through violent or erratic movements. Clinical data indicates that up to 90% of individuals who develop isolated or idiopathic RBD will eventually progress to Parkinson’s disease or a related brain disorder like dementia with Lewy bodies.

This extended preclinical window, which can span 15 to 20 years, creates a critical therapeutic window of opportunity. Researchers now believe that by intervening during the early stages of RBD, modern medicine may be able to intercept the underlying disease process before irreversible neurological damage occurs. Recent investigations conducted by Yale scientists strongly suggest that chronic inflammation within the spinal fluid plays a direct and vital role in driving this disease progression.

To test this hypothesis, the new multi-center clinical trial is evaluating adalimumab—widely known by the brand name Humira—which is already an established therapy for various chronic inflammatory and autoimmune conditions. The study, formally titled "An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons with REM Sleep Behavior Disorder" or "PRISMS," has already enrolled its initial participants and is actively recruiting individuals between the ages of 50 and 80 across 15 specialized medical centers in the United States and Canada.

According to Dr. Cedarbaum, this trial marks a historical milestone in neurology. It stands as the first clinical investigation utilizing an immunologically-based strategy to try to slow or prevent the ultimate manifestation of Parkinson’s disease.

Understanding REM Sleep Behavior Disorder

To fully grasp the significance of the PRISMS study, it is essential to understand the mechanics of normal sleep and how rapid eye movement sleep behavior disorder disrupts it. REM sleep is the specific phase of the sleep cycle during which the brain experiences its most vivid and active dreaming. The term originates from the rapid, darting movements of the eyes beneath closed eyelids as they visually track the unfolding events of a dream.

In a healthy individual, the rest of the body remains entirely motionless during this phase because the brain engages a protective physiological mechanism that induces muscle paralysis from the eyes downward. This natural paralysis prevents humans from physically acting out their internal dream states. Similar protective phenomena can be observed in animals, such as a sleeping puppy that twitches its paws or whimpers softly while inhibitory neural pathways keep full-body movement suppressed.

In individuals suffering from RBD, however, this crucial dream-paralysis mechanism breaks down entirely. The failure of this neural gatekeeper puts both the patients and their bed partners at significant risk of physical injury. Patients frequently fall out of bed, strike out, kick, or flail violently during vivid nightmares. Clinicians have also documented less violent yet bizarre instances where patients perform entirely routine, conscious-like activities while fast asleep, such as sitting up to drink a cup of coffee or mimicking the motion of smoking a cigarette.

While some cases of RBD are secondary to external triggers, such as the use of specific antidepressant medications, many patients develop the disorder spontaneously. When patients present with this form of idiopathic or isolated RBD, their risk of subsequently developing Parkinson’s disease or related synucleinopathies climbs exponentially.

Dr. Cedarbaum notes that individuals who seek medical evaluation for new-onset RBD face an annual conversion rate of approximately 6% toward Parkinson’s disease or a related neurological condition, with the transition unfolding across a decade or two.

The Pathological Cascade of Alpha-Synuclein

Emerging scientific evidence strongly points to the gastrointestinal tract as a primary staging ground for the origins of Parkinson’s disease. All human nerve cells contain a normal physiological protein known as alpha-synuclein. However, post-mortem examinations of brains from Parkinson’s patients consistently reveal dense, abnormal aggregations of this protein, commonly referred to as "Lewy bodies."

In recent years, researchers have also identified abnormal clumps of alpha-synuclein residing within nerve cells lining the gut. These misfolded protein aggregates possess the capacity to migrate toward the central nervous system through multiple anatomical pathways. The most prominent route of transmission is the vagus nerve, which establishes a direct structural connection between the stomach, intestines, and the brainstem. Additionally, protein aggregation can initiate within the olfactory bulb, providing a clear explanation for why many individuals with early Parkinson’s disease experience a profound loss of their sense of smell.

Once alpha-synuclein reaches the brainstem, it initiates a progressive, cell-to-cell propagation upward through the central nervous system. Among the earliest neural populations encountered by this spreading pathology are the brainstem circuits responsible for enforcing muscle paralysis during REM sleep—explaining why RBD frequently serves as the earliest clinical manifestation of the disease.

As the pathological protein continues its ascent, it eventually reaches a vital mid-brain structure called the substantia nigra. Located within the basal ganglia—a complex network of interconnected subcortical nuclei responsible for coordinating voluntary movement—the substantia nigra is tasked with producing and transmitting the neurotransmitter dopamine to higher brain centers. The progressive degradation of this dopaminergic system gives rise to the classic motor symptoms of Parkinson’s disease.

Dr. Cedarbaum uses a mechanical analogy to describe this delicate neural machinery, comparing the brain’s movement programming to a complex gearbox and dopamine to essential motor oil. When accumulating alpha-synuclein damages the cellular architecture of the substantia nigra, the region fails to synthesize adequate dopamine. Consequently, movement becomes progressively slower, stiffer, and prone to tremors.

While standard pharmacological treatments like levodopa are highly effective at temporarily replenishing dopamine levels and managing overt symptoms, they do not alter the underlying trajectory of alpha-synuclein propagation. Over years and decades, the protein continues its relentless climb, eventually invading cortical and cognitive regions to cause dementia. The emergence of RBD acts as an early warning siren signaling that this destructive biological process is already well underway, providing a vital window for early therapeutic intervention.

Uncovering the Role of Inflammation

While the physical spread of alpha-synuclein represents a major component of Parkinson’s disease pathology, researchers are increasingly recognizing that neuroinflammation is a critical partner in driving neuronal injury. Dr. Cedarbaum spent much of his distinguished career searching for ways to preserve dopamine-producing neurons, eventually collaborating with Dr. David Hafler, a world-renowned authority on multiple sclerosis whose pioneering immunological work transformed the therapeutic landscape of that autoimmune condition.

Recognizing striking similarities between the early clinical presentation of RBD and the formative stages of multiple sclerosis, Hafler and Cedarbaum secured a major research grant in 2021 from the Aligning Science Across Parkinson’s (ASAP) network. The team conducted detailed spinal fluid analyses comparing cohorts of participants with RBD, established Parkinson’s disease, and mixed presentations against healthy controls and multiple sclerosis patients.

The biochemical analyses revealed significantly elevated white blood cell counts—a definitive marker of inflammation—within the spinal fluid of participants diagnosed with RBD. Interestingly, this acute inflammatory signature was largely absent in patients with advanced Parkinson’s disease, mirroring the disease kinetics observed in multiple sclerosis. Dr. Hafler notes that during the early autoimmune phase of multiple sclerosis, clinicians similarly observe prominent white blood cell infiltration in the spinal fluid, whereas later stages transition into a predominantly neurodegenerative state characterized by reduced inflammation and accumulating cellular loss.

Further advanced analyses of these spinal fluid cells using single-cell RNA sequencing pinpointed specific cellular populations in which pro-inflammatory genes were overtly activated. These cells functioned as receptors for tumor necrosis factor (TNF), a prominent signaling protein known to drive a wide range of autoimmune conditions, including rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

This discovery provided compelling evidence that inflammation, particularly pathways mediated by TNF, plays a crucial mechanistic role during the earliest phases of Parkinson’s disease pathogenesis. Intriguingly, epidemiological data has long shown that individuals suffering from systemic autoimmune disorders like rheumatoid arthritis and inflammatory bowel disease face an elevated risk of developing Parkinson’s disease. However, patients treated with targeted anti-TNF therapies like adalimumab exhibit a reduced risk comparable to that of the general population.

These converging lines of evidence led Yale researchers to hypothesize that adalimumab might effectively interrupt the destructive neuroinflammatory cascade contributing to Parkinson’s disease. Dr. Ronald Postuma, a professor of neurology at McGill University and the principal investigator for the PRISMS study in Canada, emphasizes that tamping down an overactive immune response early in the disease course could prevent bystander damage, where immune cells erroneously attack vulnerable neuronal tissue.

Inside the PRISMS Clinical Trial

The PRISMS study is coordinated by a powerful collaborative network, with the clinical trial coordinating center stationed at the Center for Health Technology at the University of Rochester. The trial encompasses 14 academic medical centers across the United States, including Yale, alongside one participating site in Canada as part of the esteemed Parkinson Study Group.

To qualify for enrollment in the rigorous trial, candidates must possess a confirmed diagnosis of rapid eye movement sleep behavior disorder verified through objective polysomnography, or a comprehensive sleep study. Furthermore, to maximize the certainty that underlying alpha-synuclein pathology is driving the condition, candidates are evaluated for hyposmia, or a diminished sense of smell. While definitive confirmation of Lewy bodies traditionally requires invasive procedures such as spinal taps or skin biopsies, clinical studies demonstrate that individuals presenting with both confirmed RBD and olfactory loss possess a greater than 90% probability of harboring underlying synuclein pathology. Consequently, meeting both criteria is mandatory for trial eligibility.

Once enrolled, participants are randomly assigned to self-administer either subcutaneous injections of adalimumab or a matching placebo every two weeks over a sustained two-year treatment period. Throughout the course of the study, participants visit their respective clinical sites approximately nine times to complete comprehensive health evaluations, cognitive assessments, and detailed movement pattern analyses. Routine blood draws are conducted at each visit to monitor immune cell function and track circulating biomarkers related to Parkinson’s disease progression. Additionally, a subset of participants undergoes annual lumbar punctures to evaluate changes in spinal fluid composition, including the aggregation state of alpha-synuclein.

Participants also undergo three distinct brain imaging procedures annually. Two of these scans, including a specialized magnetic resonance imaging (MRI) examination, are designed to assess the functional integrity of the brain’s dopamine system. A third imaging modality measures regional cerebral glucose metabolism using a safe, minimal tracer dose of radioactive sugar. The brains of individuals developing Parkinson’s disease exhibit distinct, abnormal patterns of energy consumption in specific anatomical regions years before motor symptoms appear, providing a measurable biomarker of disease progression.

Dr. Cedarbaum notes that if the therapeutic regimen successfully prevents the worsening of these abnormal metabolic patterns or halts the degradation of dopamine signaling pathways, researchers will have strong preliminary evidence that the drug is effectively modifying the disease course.

As with any potent biological therapy, adalimumab carries known risks and potential side effects. The medication is associated with an increased susceptibility to certain infections, including tuberculosis and hepatitis, as well as a slightly elevated risk of specific malignancies and rare neurological complications mimicking multiple sclerosis symptoms. Trial investigators maintain rigorous safety protocols to closely monitor participants for any adverse events throughout the duration of the study.

Current pharmacological treatments for Parkinson’s disease remain limited to symptomatic management, failing entirely to alter the underlying neurodegenerative cascade. By targeting the fundamental biological processes of the disease before motor impairment even begins, researchers hope to shift the paradigm of neurological care. Dr. Hafler draws a parallel to advancements in multiple sclerosis therapeutics, noting that very early intervention has achieved remarkable efficacy in halting disease progression, an ambitious benchmark the research team hopes to replicate in the field of Parkinson’s disease.

Funding for the PRISMS trial is provided by generous grants from the Marcus Foundation and the National Institute on Aging. Additional details regarding study protocols, specific site locations, and comprehensive eligibility criteria are accessible through clinicaltrials.gov and the official Yale School of Medicine study webpage.

Nana

Penulis aktif di HypePress yang membagikan konten inspiratif, informasi terkini, dan gaya hidup untuk generasi muda.

Artikel Bermanfaat dan Menghibur Lainnya